Delstrigo

Medical Editor: John P. Cunha, DO, FACOEP Last updated on RxList: 11/1/2021
Delstrigo Side Effects Center

Medical Editor: John P. Cunha, DO, FACOEP

What Is Delstrigo?

Delstrigo (doravirine, lamivudine, and tenofovir disoproxil fumarate) is a three-drug combination of a non-nucleoside reverse transcriptase inhibitor [NNRTI]), and two nucleoside analogue reverse transcriptase inhibitors indicated as a complete regimen for the treatment of HIV-1 infection in adult patients with no antiretroviral treatment history.

What Are Side Effects of Delstrigo?

Common side effects of Delstrigo include:

  • dizziness,
  • nausea,
  • abnormal dreams,
  • insomnia,
  • diarrhea,
  • drowsiness, and
  • rash

Dosage for Delstrigo

The recommended adult dosage of Delstrigo is one tablet taken orally once daily with or without food.

What Drugs, Substances, or Supplements Interact with Delstrigo?

Delstrigo may interact with other antiretroviral medications for treatment of HIV-1 infection, enzalutamide, anticonvulsants, rifampin or rifapentine, mitotane, hepatitis C antiviral agents, St. John's wort, sorbitol, high-dose or multiple nonsteroidal anti-inflammatory drugs (NSAIDs), and aminoglycosides. Tell your doctor all medications and supplements you use.

Delstrigo During Pregnancy or Breastfeeding

Tell your doctor if you are pregnant or plan to become pregnant before using Delstrigo; it is unknown how it would affect a fetus. There is a pregnancy exposure registry that monitors pregnancy outcomes in individuals exposed to Delstrigo during pregnancy. It is unknown if Delstrigo passes into breast milk, however, breastfeeding is not recommended while using Delstrigo due to the potential for HIV transmission.

Additional Information

Our Delstrigo (doravirine, lamivudine, and tenofovir disoproxil fumarate) Tablets, for Oral Use Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

QUESTION

What is HIV? See Answer
Delstrigo Consumer Information

3 pharmacies near 20147 have coupons for Delstrigo (Brand Names:Delstrigo for 30 Tablets)

Walmart Pharmacy
Walmart Pharmacy
$3811.7

Est. Regular Price

$2288.06

with free coupon

View Coupon
CVS Pharmacy
CVS Pharmacy
$2754.75

Est. Regular Price

$2396.18

with free coupon

View Coupon
Costco
Costco
$2754.75

Est. Regular Price

$2400.46

with free coupon

View Coupon

Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Call your doctor at once if you have:

  • urinating more or less than usual;
  • increased thirst;
  • new or worsening bone pain;
  • muscle pain or weakness; or
  • pain in your arms, legs, hands, or feet.

Doravirine, lamivudine, and tenofovir affects your immune system, which may cause certain side effects (even weeks or months after you've taken this medicine). Tell your doctor if you have:

  • signs of a new infection--fever, night sweats, swollen glands, cold sores, cough, wheezing, diarrhea, weight loss;
  • trouble speaking or swallowing, problems with balance or eye movement, weakness or prickly feeling; or
  • swelling in your neck or throat (enlarged thyroid), menstrual changes, impotence.

Common side effects may include:

  • nausea;
  • dizziness; or
  • strange dreams.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Read the entire detailed patient monograph for Delstrigo (Doravirine, Lamivudine, and Tenofovir Disoproxil Fumarate Tablets)

SLIDESHOW

A Timeline of the HIV/AIDS Pandemic See Slideshow
Delstrigo Professional Information

SIDE EFFECTS

The following adverse reactions are discussed in other sections of the labeling:

  • Severe Acute Exacerbation of Hepatitis B in Patients Coinfected with HIV-1 and HBV [see WARNINGS AND PRECAUTIONS]
  • New Onset or Worsening Renal Impairment [see WARNINGS AND PRECAUTIONS]
  • Bone Loss and Mineralization Defects [see WARNINGS AND PRECAUTIONS]
  • Immune Reconstitution Syndrome [see WARNINGS AND PRECAUTIONS]

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Adverse Reactions In Adults With No Antiretroviral Treatment History

The safety assessment of DELSTRIGO is based on Week 48 data from two Phase 3, randomized, international, multicenter, double-blind, active-controlled trials. A total of 747 subjects received doravirine either as the single entity in combination with other antiretroviral drugs as background regimens (n=383) or as the fixed-dose DELSTRIGO (n=364), and a total of 747 subjects were randomized to control arms.

In DRIVE-AHEAD (Protocol 021), 728 adult subjects received either DELSTRIGO (n=364) or EFV/FTC/TDF once daily (n=364). By Week 48, 3% in the DELSTRIGO group and 6% in the EFV/FTC/TDF group had adverse events leading to discontinuation of study medication.

Adverse reactions reported in greater than or equal to 5% of subjects in any treatment group in DRIVEAHEAD are presented in Table 1.

Table 1: Adverse Reactions* (All Grades) Reported in ≥5% of Subjects in Any Treatment Group in Adults with No Antiretroviral Treatment History in DRIVE-AHEAD (Week 48)

  DELSTRIGO
Once Daily
N=364
EFV/FTC/TDF
Once Daily
N=364
Dizziness 7% 32%
Nausea 5% 7%
Abnormal Dreams 5% 9%
Insomnia 4% 5%
Diarrhea 3% 5%
Somnolence 3% 7%
Rash 2% 12%
*Frequencies of adverse reactions are based on all adverse events attributed to trial drugs by the investigator.
No adverse reactions of Grade 2 or higher (moderate or severe) occurred in ≥2% of subjects treated with DELSTRIGO.
Rash: includes rash, rash erythematous, rash generalized, rash macular, rash maculopapular, rash papular, rash pruritic.

The majority (65%) of adverse reactions associated with DELSTRIGO occurred at severity Grade 1 (mild).

Neuropsychiatric Adverse Events

For DRIVE-AHEAD, the analysis of subjects with neuropsychiatric adverse events by Week 48 is presented in Table 2. The proportion of subjects who reported one or more neuropsychiatric adverse events was 24% and 57% in the DELSTRIGO and EFV/FTC/TDF groups, respectively.

A statistically significantly lower proportion of DELSTRIGO-treated subjects compared to EFV/FTC/TDFtreated subjects reported neuropsychiatric adverse events by Week 48 in the three pre-specified categories of dizziness, sleep disorders and disturbances, and altered sensorium.

Table 2: DRIVE-AHEAD - Analysis of Subjects with Neuropsychiatric Adverse Events* (Week 48)

  DELSTRIGO Once Daily
N=364
EFV/FTC/TDF Once Daily
N=364
Treatment Difference (DELSTRIGO - EFV/FTC/TDF)
Estimate (95% CI)
Sleep disorders and disturbances 12% 26% -13.5
(-19.1, -7.9)
Dizziness 9% 37% -28.3
(-34.0, -22.5)
Altered sensorium§ 4% 8% -3.8
(-7.6, -0.3)
*All causality and all grade events were included in the analysis.
The 95% CIs were calculated using Miettinen and Nurminen's method. Categories pre-specified for statistical testing were dizziness (p <0.001), sleep disorders and disturbances (p <0.001), and altered sensorium (p=0.033).
Predefined using MedDRA preferred terms including: abnormal dreams, hyposomnia, initial insomnia, insomnia, nightmare, sleep disorder, somnambulism.
§Predefined using MedDRA preferred terms including: altered state of consciousness, lethargy, somnolence, syncope.

Neuropsychiatric adverse events in the pre-defined category of depression and suicide/self-injury were reported in 4% and 7% of subjects, in the DELSTRIGO and EFV/FTC/TDF groups, respectively.

In DRIVE-AHEAD through 48 weeks of treatment, the majority of subjects who reported neuropsychiatric adverse events reported events that were mild to moderate in severity (97% [83/86] and 96% [198/207], in the DELSTRIGO and EFV/FTC/TDF groups, respectively) and the majority of subjects reported these events in the first 4 weeks of treatment (72% [62/86] in the DELSTRIGO group and 86% [177/207] in the EFV/FTC/TDF group).

Neuropsychiatric adverse events led to treatment discontinuation in 1% (2/364) and 1% (5/364) of subjects in the DELSTRIGO and EFV/FTC/TDF groups, respectively. The proportion of subjects who reported neuropsychiatric adverse events through Week 4 was 17% (62/364) in the DELSTRIGO group and 49% (177/364) in the EFV/FTC/TDF group. At Week 48, the prevalence of neuropsychiatric adverse events was 12% (44/364) in the DELSTRIGO group and 22% (81/364) in the EFV/FTC/TDF group.

Laboratory Abnormalities

The percentages of subjects with selected laboratory abnormalities (that represent a worsening from baseline) who were treated with DELSTRIGO or EFV/FTC/TDF in DRIVE-AHEAD are presented in Table 3.

Table 3: Selected Laboratory Abnormalities Reported in Adult Subjects with No Antiretroviral Treatment History in DRIVE-AHEAD (Week 48)

Laboratory Parameter Preferred Term (Unit)/Limit DELSTRIGO Once Daily
N=364
EFV/FTC/TDF Once Daily
N=364
Blood Chemistry
Total bilirubin 4% 0%
1.1 - <1.6 x ULN 2% 0%
1.6 - <2.6 x ULN ≥2.6 x ULN <1% <1%
Creatinine (mg/dL)
>1.3 - 1.8 x ULN or Increase of >0.3 mg/dL above baseline 2% 1%
>1.8 x ULN or Increase of ≥1.5 x above baseline 2% 1%
Aspartate aminotransferase (IU/L)
2.5 - <5.0 x ULN 2% 2%
≥5.0 x ULN <1% 2%
Alanine aminotransferase (IU/L)
2.5 - <5.0 x ULN 3% 4%
≥5.0 x ULN <1% 2%
Alkaline phosphatase (IU/L)
2.5 - <5.0 x ULN 0% <1%
≥5.0 x ULN 0% <1%
Lipase
1.5 - <3.0 x ULN 5% 4%
≥3.0 x ULN 1% 2%
Creatine kinase (IU/L)
6.0 - <10.0 x ULN 2% 2%
≥10.0 x ULN 2% 3%
Cholesterol, fasted (mg/dL)
≥300 mg/dL <1% <1%
LDL cholesterol, fasted (mg/dL)
≥190 mg/dL <1% 2%
Triglycerides, fasted (mg/dL)
>500 mg/dL <1% 3%
ULN = Upper limit of normal range.

Change in Lipids from Baseline

For DRIVE-AHEAD, changes from baseline at Week 48 in LDL-cholesterol, non-HDL-cholesterol, total cholesterol, triglycerides, and HDL-cholesterol are shown in Table 4.

The LDL and non-HDL comparisons were pre-specified and are summarized in Table 4. The differences were statistically significant, showing superiority of DELSTRIGO for both parameters. The clinical benefit of these findings has not been demonstrated.

Table 4: Mean Change from Baseline in Fasting Lipids in Adult Subjects with No Antiretroviral Treatment History in DRIVE-AHEAD (Week 48)

Laboratory Parameter Preferred Term DELSTRIGO Once Daily
N=320
EFV/FTC/TDF Once Daily
N=307
Difference Estimates
(DELSTRIGO - EFV/FTC/TDF)
  Baseline Change Baseline Change Difference (95% CI)
LDL-Cholesterol (mg/dL)* 91.7 -2.1 91.3 8.3 -10.2 (-13.8, -6.7)
Non-HDL Cholesterol (mg/dL)* 114.7 -4.1 115.3 12.7 -16.9 (-20.8, -13.0)
Total Cholesterol (mg/dL) 156.8 -2.2 156.8 21.1 -
Triglycerides (mg/dL) 118.7 -12.0 122.6 21.6 -
HDL-Cholesterol (mg/dL) 42.1 1.8 41.6 8.4 -
Subjects on lipid-lowering agents at baseline were excluded from these analyses (DELSTRIGO n=15 and EFV/FTC/TDF n=10).
Subjects initiating a lipid-lowering agent post-baseline had their last fasted on-treatment value (prior to starting the agent) carried forward (DELSTRIGO n=3 and EFV/FTC/TDF n=8).
*P-value for the pre-specified hypothesis testing for treatment difference was <0.0001.
Not pre-specified for hypothesis testing.

Adverse Reactions In Virologically-Suppressed Adults

The safety of DELSTRIGO in virologically-suppressed adults was based on Week 48 data from 670 subjects in the DRIVE-SHIFT trial (Protocol 024), a randomized, international, multicenter, open-label trial in which virologically-suppressed subjects were switched from a baseline regimen consisting of two nucleoside reverse transcriptase inhibitors (NRTIs) in combination with a protease inhibitor (PI) plus either ritonavir or cobicistat, or elvitegravir plus cobicistat, or an NNRTI to DELSTRIGO. Overall, the safety profile in virologically-suppressed adult subjects was similar to that in subjects with no antiretroviral treatment history.

Laboratory Abnormalities

Serum ALT and AST Elevations

In the DRIVE-SHIFT trial, 22% and 16% of subjects in the immediate switch group experienced ALT and AST elevations of greater than 1.25 X ULN, respectively, through 48 weeks on DELSTRIGO. For these ALT and AST elevations, no apparent time patterns with regard to time to onset relative to switch were observed. One percent of subjects had ALT or AST elevations greater than 5 X ULN through 48 weeks on DELSTRIGO. The ALT and AST elevations were generally asymptomatic, and not associated with bilirubin elevations. In comparison, 4% and 4% of subjects in the delayed switch group experienced ALT and AST elevations of greater than 1.25 X ULN through 24 weeks on their baseline regimen.

Change In Lipids From Baseline

Changes from baseline at Week 24 in LDL-cholesterol, non-HDL-cholesterol, total cholesterol, triglycerides, and HDL-cholesterol in subjects on a PI plus ritonavir-based regimen at baseline are shown in Table 5. The LDL and non-LDL comparisons were pre-specified, and the differences were statistically significant, showing superiority for an immediate switch to DELSTRIGO for both parameters. The clinical benefit of these findings has not been demonstrated.

Table 5: Mean Change from Baseline in Fasting Lipids in Adult Virologically-Suppressed Subjects on a PI plus Ritonavir-based Regimen at Baseline in DRIVE-SHIFT (Week 24)

Laboratory Parameter Preferred Term DELSTRIGO (Week 0-24) Once Daily
N=244
PI+ritonavir (Week 0-24) Once Daily
N=124
Difference Estimates
  Baseline Change Baseline Change Difference (95% CI)
LDL-Cholesterol (mg/dL)* 108.7 -16.3 110.5 -2.6 -14.5 (-18.9, -10.1)
Non-HDL Cholesterol (mg/dL)* 138.6 -24.8 138.8 -2.1 -22.8 (-27.9, -17.7)
Total Cholesterol (mg/dL) 188.5 -26.1 187.4 -0.2 -
Triglycerides (mg/dL) 153.1 -44.4 151.4 -0.4 -
HDL-Cholesterol (mg/dL) 50.0 -1.3 48.5 1.9 -
Subjects on lipid-lowering agents at baseline were excluded from these analyses (DELSTRIGO n=26 and PI+ritonavir n=13).
Subjects initiating a lipid-lowering agent post-baseline had their last fasted on-treatment value (prior to starting the agent) carried forward (DELSTRIGO n=4 and PI+ritonavir n=2).
*P-value for the pre-specified hypothesis testing for treatment difference was <0.0001.
Not pre-specified for hypothesis testing.

Postmarketing Experience

The following adverse reactions have been identified during postmarketing experience in patients receiving lamivudine- or TDF-containing regimens. Because postmarketing reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Lamivudine:

Body as a Whole: redistribution/accumulation of body fat

Endocrine and Metabolic: hyperglycemia

General: Weakness

Hemic and Lymphatic: anemia (including pure red cell aplasia and severe anemias progressing on therapy)

Hepatic and Pancreatic: lactic acidosis and hepatic steatosis, posttreatment exacerbations of hepatitis B

Hypersensitivity: anaphylaxis, urticaria

Musculoskeletal: muscle weakness, CPK elevation, rhabdomyolysis

Skin: alopecia, pruritus

TDF

Immune System Disorders: allergic reaction, including angioedema

Metabolism and Nutrition Disorders: lactic acidosis, hypokalemia, hypophosphatemia

Respiratory, Thoracic, and Mediastinal Disorders: dyspnea

Gastrointestinal Disorders: pancreatitis, increased amylase, abdominal pain

Hepatobiliary Disorders: hepatic steatosis, hepatitis, increased liver enzymes (most commonly AST, ALT gamma GT)

Skin and Subcutaneous Tissue Disorders: rash

Musculoskeletal and Connective Tissue Disorders: rhabdomyolysis, osteomalacia (manifested as bone pain and which may contribute to fractures), muscular weakness, myopathy

Renal and Urinary Disorders: acute renal failure, renal failure, acute tubular necrosis, Fanconi syndrome, proximal renal tubulopathy, interstitial nephritis (including acute cases), nephrogenic diabetes insipidus, renal insufficiency, increased creatinine, proteinuria, polyuria

General Disorders and Administration Site Conditions: asthenia

The following adverse reactions, listed under the body system headings above, may occur as a consequence of proximal renal tubulopathy: rhabdomyolysis, osteomalacia, hypokalemia, muscular weakness, myopathy, hypophosphatemia.

Read the entire FDA prescribing information for Delstrigo (Doravirine, Lamivudine, and Tenofovir Disoproxil Fumarate Tablets)

© Delstrigo Patient Information is supplied by Cerner Multum, Inc. and Delstrigo Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.

Health Solutions From Our Sponsors